Introduction
Adrenomedullin was originally isolated from human pheochromocytoma based on its ability to raise intracellular cyclic (c)AMP levels in platelets (1) . Adrenomedullin belongs to a calcitonin supergene family that includes calcitonin gene-related peptide (CGRP) and amylin (2, 3) . Although initially identified as a potent vasodilator peptide, subsequent studies have demonstrated that adrenomedullin exerts diverse biological actions, such as diuresis/natriuresis (4-6), hormone secretion (7) (8) (9) , cell growth, differentiation and apoptosis (10) (11) (12) (13) .
Human adrenomedullin, synthesized from a 185-aminoacid preproadrenomedullin, is a 52-residue peptide with an intramolecular disulfide bridge and an amidated tyrosine residue at the carboxy terminus (1, 14) . Preproadrenomedullin contains a 21-amino-acid signal peptide sequence that immediately precedes a 20-amino-acid amidated peptide designated proadrenomedullin NH2-terminal 20 peptide (15) . The gene encoding preproadrenomedullin, mapped on chromosome 11, is ubiquitously expressed. Many tumor cell lines also express the adrenomedullin mRNA and/or protein (12) . Adrenomedullin has been shown to circulate in human variety of tissues and cells in the cardiovascular system (17) . Expression of adrenomedullin and its functional receptors in vascular endothelial cells (29) (30) (31) , vascular smooth muscle cells (VSMCs) (32, 33) , and fibroblasts (34) suggests the autocrine/paracrine mode of its vascular effects. Endothelial cells are considered to be an important source of plasma adrenomedullin, and adrenomedullin induces endothelial NO generation and other actions in the vascular system (17) .
It has been suggested that adrenomedullin plays a role in angiogenesis in vivo. In adrenomedullin gene knockout mice, the null phenotype is embryonically lethal due to the absence of placental vascularization; the basement membrane is absent in the aorta and cervical artery, and the endothelial cells are detached from the basement structure (35) . These results suggested that adrenomedullin is essential for the vascular morphogenesis during embryonic development, although endothelial cells are present in adrenomedullin null mice. An in vitro cell culture experiment has also suggested that adrenomedullin is not involved in either stimulation of cell proliferation or induction of DNA synthesis in endothelial cells (11) .
Adrenomedullin appears to either stimulate or inhibit cell proliferation depending on the particular cell type. With respect to the effects of adrenomedullin on VSMCs, studies have reported conflicting results. An initial report suggested that adrenomedullin had an antiproliferative effect; i.e., in serum-stimulated, growing VSMCs, addition of adrenomedullin suppressed thymidine incorporation, and this effect appeared to be mediated by cAMP stimulation (36) . A recent study suggested that adrenomedullin antagonized platelet-derived growth factor (PDGF)-stimulated mitogenesis in a subpopulation of VSMCs from the pulmonary artery, but not in other VSMCs (37) . On the other hand, adrenomedullin exerts a potent mitogenic effect in serum-deprived VSMCs (10, 38) . When rendered quiescent by serum deprivation, VSMCs respond to adrenomedullin by synthesizing DNA and proliferating. These responses are independent of cAMP activation, but mediated by initial protein tyrosine phosphorylation and subsequent p42/p44 mitogen-activated protein kinase (MAPK) activation (10) . Adrenomedullin has been shown to rapidly and transiently phosphorylate proline-rich tyrosine kinase 2 (PYK2) via autophosphorylation; in the same study, adrenomedullin promoted the association between tyrosine-phosphorylated PYK2 and the adaptor proteins Shc and Grb2, activated c-Src, and enhanced the association between c-Src and tyrosine-phosphorylated PYK2 (38) . These observations suggest that adrenomedullin stimulates PYK2 which, in turn, activates c-Src and induces recruitment of adaptor proteins (Shc/Grb2), thereby leading to activation of the Ras-dependent MAPK cascade in VSMCs (38) (Fig. 1A) . Such features of adrenomedullin as the stimulation of mitogenesis in quiescent cells while suppressing cells in the G2/M phase of the cell cycle are characteristic of growth factors, although unlike most other growth factors, adrenomedullin appears to suppress VSMC growth via stimulation of cAMP.
An in vivo role of endogenous adrenomedullin in the neointima after angioplasty has been demonstrated by infusion of the adrenomedullin/CGRP receptor antagonist, CGRP , to rats (39) . Following balloon injury of the common carotid arteries, the expression of adrenomedullin was elevated at 2 days and further enhanced in the hyperplastic intima at 7 days, while neointimal hyperplasia developed within 7 days. However, both adrenomedullin expression and neointimal thickening were markedly suppressed by treatment with CGRP . At 7 days after injury, 
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CGRP(8-37) reduced the neointimal cross-sectional area by 61%, and BrdU-positive nuclei in the neointima were markedly reduced in CGRP(8-37)-treated arteries. The results suggest that inhibition of neointimal hyperplasia by CGRP(8-37) is mainly due to its blockade of endogenous adrenomedullin acting upon the proliferative VSMCs after balloon injury.
Accumulating lines of evidence support a role for adrenomedullin as a potent growth factor in a number of non-tumor cell types. These include fetal rat osteoblasts (40) , neonatal mouse calvaria (40) , rat adrenal zona glomerulosa cells (41, 42) , fibroblasts (34, 43) , and several epithelial cells of the normal skin, including keratinocytes of the epidermis and hair follicles, and the cells of the glands and secretory ducts (25) . The mitogenic activity of adrenomedullin in many of the above-mentioned cells appears to be mediated via MAPK activation (41, 42) .
An autocrine/paracrine role of adrenomedullin as a tumor growth factor has been more extensively studied (12, 44) . Adrenomedullin synthesized and secreted from a variety of tumor tissues and cells (12, 22, (24) (25) (26) (45) (46) (47) stimulates the proliferation of skin tumors (25) , oral squamous cell carcinoma (48), teratocarcinoma (49), Conn's adenoma cells (50) , prostate cancer cells (51) , non-small cell lung carcinoma (12, 22) , breast carcinoma (12) and ovarian carcinoma (12) .
Although there is overwhelming evidence that adrenomedullin promotes cellular growth, in certain cell types, there is also evidence that adrenomedullin suppresses mitogenesis. In rat mesangial cells, adrenomedullin inhibits mitogenesis even under quiescence and suppresses MAPK activity (52, 53) . In cultured neonatal rat cardiocytes and cardiac fibroblasts, adrenomedullin suppresses cell growth (54, 55) . Certain cancer cells do not proliferate in response to adrenomedullin, and some of these cell lines show a growth-inhibitory response with elevation of intracellular cAMP (56) . Differential growth responses to adrenomedullin in each cell type and/or experimental condition appear to be dependent upon intracellular signaling machinery downstream of adrenomedullin receptors. For example, in cells lacking MAPK activation signaling machinery, stimulation of adrenomedullin receptors results in marked activation of cAMP, leading to inhibition of cell growth, while in the majority of cell types reported, the MAPK pathway is coupled to the adrenomedullin receptor, and the magnitude of growth stimulatory signaling exceeds the growth inhibitory signals by cAMP activation, thereby resulting in a net proliferative response (Fig. 1) .
Regulation of Apoptosis by Adrenomedullin
Many cell types undergo apoptosis when they are deprived of growth factors, while addition of major growth factor(s), such as PDGF, insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), inhibits apoptosis. Various stimuli, such as serum deprivation, radiation, chemotherapeutic agents and antioxidants, induce apoptosis in many cell types (57-60), whereas growth factors and cytokines may modulate apoptosis triggered by such environmental signals (61) (62) (63) (64) (65) (66) . Within individual growth factors, the potency for inducing cell division is not always equal to that for antagonizing apoptosis whereas some growth factors may induce cell division without antagonizing apoptosis, or vice versa, and thus these two effects are considered discrete cell-survival factors. However, it has recently been revealed that even vasoactive peptides possessing mitogenic activity also show antiapoptotic activity. For example, endothelin-1 was the first peptide to be shown to inhibit serum-deprivation-induced apoptosis in endothelial cells (67) , diploid fibroblasts (68) , and VSMCs (69) .
Almost simultaneously with our initial discovery of anti-
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Fig. 2. Signaling of apoptosis by adrenomedullin in endothelial cells. Adrenomedullin protects against serum-deprivation-induced apoptosis by upregulating an antiapoptotic protein, max, independently from cAMP activation.
apoptosis by endothelin, adrenomedullin was shown to act as an autocrine/paracrine apoptosis survival factor for vascular endothelial cells, although its potency was slightly less than that of endothelin-1 (11) . Protection of endothelial apoptosis by adrenomedullin is mediated via a cAMP-independent mechanism, based on the finding that agents capable of elevating or mimicking cAMP, such as forskolin or prostaglandin I2, did not inhibit apoptosis, whereas cAMP antagonists failed to block the adrenomedullin-induced antiapoptotic effect (11) . Subsequent studies have confirmed that adrenomedullin has a similar antiapoptotic activity independent of cAMP in human umbilical endothelial cells (70) . Recently, a novel mechanism for the antiapoptotic activity of adrenomedullin was documented in our laboratory. Using the real-time quantitative RT-PCR method, adrenomedullin was demonstrated to induce a helix-loop-helix leucine zipper protein, max, which is a heterodimeric partner of c-myc oncogene. Unlike other growth factors, adrenomedullin did not induce the c-myc oncogene in endothelial cells, and the resulting max dominance leads to resistance to apoptosis (13) (Fig. 2) .
In endometrial cancer cells, adrenomedullin has been reported to increase resistance to hypoxia-induced apoptosis via an upregulation of the antiapoptotic protein, Bcl-2 (71). In human adrenal zona glomerulosa cells, adrenomedullin decreased apoptotic cell death (72) . In glomerular mesangial cells, however, both adrenomedullin and cAMP agonists can induce apoptosis, and the effect appears to be mediated via activation of cAMP, since a protein kinase A (PKA) inhibitor has been shown to block apoptosis induced by adrenomedullin (73) . p38 MAPK has also been proposed to mediate the proapoptotic effect of adrenomedullin in mesangial cells (74) . Such proapoptotic activity of adrenomedullin is not a feature common to other types of cells, but appears to be restricted to mesangial cells, at least at the present moment. Thus, the exact spectrum of target cell types in which adrenomedullin modulates apoptosis remains to be determined. Furthermore, the mechanisms by which adrenomedullin mediates antiapoptotic vs. proapoptotic signaling will require further investigation.
The physiological significance of the antiapoptotic or proapoptotic effects of adrenomedullin remain to be determined. Since adrenomedullin is actively synthesized and secreted from the vasculature, it is hypothesized that the local adrenomedullin concentration under various pathological states may protect the vascular endothelial cells against many insults in an autocrine/paracrine manner. By contrast, since abnormal proliferation of glomerular mesangial cells leads to the development of several glomerular diseases, apoptotic elimination of mesangial cells by adrenomedullin may serve to prevent the occurrence of mesangial proliferation. It is possible that adrenomedullin could play beneficial roles in retarding endothelial injury and progression of renal disease.
Concluding Remarks
The ability to modulate both cellular proliferation and apoptosis has been recognized as one of the features of the multifunctional regulatory peptide, adrenomedullin (17) . There has been extensive investigation into the regulation of mitogenesis by this peptide, with most of the results suggesting that adrenomedullin promotes cellular growth via the protein tyrosine kinase (PTK)/MAPK pathway, although it also shows a growth-inhibitory effect on certain cell types via a cAMP-dependent mechanism. The effect of adrenomedullin on apoptosis has been less intensively studied; adrenomedullin appears to antagonize apoptosis in the great majority of cells examined, whereas it may promote apoptosis in a few cell types. Thus, adrenomedullin may play a dual role either as a growth promoting/antiapoptotic factor or as a growth-inhibitory/proapoptotic factor in a cell-specific manner. Since vascular endothelial cells, VSMCs, fibroblasts and cardiomyocytes secrete adrenomedullin and express its receptors, an autocrine/paracrine role for adrenomedullin to regulate cell growth and apoptosis of the cardiovascular tissues has been suggested. Adrenomedullin utilizes several intracellular signaling pathways, such as cAMP, nitric oxide/cGMP and PTK/MAPK. Among these, PTK appears to play the key role in the regulation of cell growth and apoptosis by adrenomedullin.
